Evaluation of the efficacy and safety of botulinum toxin type A to induce temporary ptosis in dogs.

Autor:	Bittencourt MK; Department of Ophthalmology, School of Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. maurakwb@yahoo.com.br, de Vasconcellos JP, Bittencourt MD, Malagó R, Bacellar M
Jazyk:	angličtina
Zdroj:	Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2013 May; Vol. 29 (4), pp. 431-6. Date of Electronic Publication: 2013 Jan 16.
DOI:	10.1089/jop.2012.0119
Abstrakt:	Purpose: To verify the safety and efficacy of botulinum toxin type A (BoNT/A) to promote protective ptosis in dogs. Methods: In this prospective interventional study, a total of 10 dogs underwent transcutaneous anterior chemodenervation of levator palpebral superioris with 15 U of BoNT/A. The systemic changes, ocular mobility, visual function, intraocular pressure (IOP), tear production, and the onset, degree, and duration of ptosis were evaluated on a daily basis during the first 7 days and on days 14, 21, and 28 after application. Results: The onset of the clinical effect was observed between 2 and 3 days after application of the toxin; the time taken for maximum ptosis to develop varied from 4 to 7 days (mean 5 days) and the average duration of the toxin effect was 21 days. The mean percentage reduction in palpebral fissure height was 42.859% (SD±35.714%-59.821%). There was not a statistically significant difference in IOP before and after the BoNT/A application (P=0.974), or lacrimal production evaluation (P=0.276). There was no change in ocular mobility and no other adverse effect was observed in association with the administration of the study drug. Conclusion: The application of BoNT/A into the levator palpebral superioris muscle in dogs was effective and safe to promote protective ptosis with a temporary covering of the cornea.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu